



Mylan Nominates Neil Dimick to Its Board of Directors

PITTSBURGH, Sept. 15 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced the nomination of Neil Dimick to the Mylan Board of Directors.

Mr. Dimick, 56, served as Executive Vice President and Chief Financial Officer of AmerisourceBergen Corporation until his retirement in 2002. Mr. Dimick previously served as Senior Vice President and Chief Financial Officer of Bergen Brunswig Corporation from 1992 until August of 2001, at which time he was instrumental in negotiating and planning Bergen's merger with AmeriSource Health Corporation to create AmerisourceBergen, one of the largest pharmaceutical services companies in the United States with annual revenues in excess of \$50 billion. Mr. Dimick also spent 18 years at Deloitte & Touche, including eight years as a partner.

Mr. Dimick currently serves on the Board of Directors of WebMD, owner of the world's most used health care Internet portal and physicians' practice management system, Alliance Imaging, America's leading provider of diagnostic imaging services, Thoratec Corporation, a leading device manufacturer for the treatment of heart failure, and Resources Connection, Inc., an international professional services firm.

Milan Puskar, Mylan's Chairman, commented: "Neil will be a valuable addition to the Mylan Board. He has a detailed knowledge of the pharmaceutical industry and has extensive capital markets experience. We look forward to benefiting from his industry knowledge and perspective on the board."

Mr. Dimick will be on the ballot for election at Mylan's Annual Shareholders Meeting on October 28, 2005. He is standing for election to the Board seat vacated by Laurence S. DeLynn, who will retire from the Mylan Board as of October 28. Mr. DeLynn has served on the Mylan Board since 1975.

"We thank Laurence for his 30 years of dedication and service to Mylan," said Mr. Puskar. "He has been a valuable member of the Board as Mylan has transformed into a leading force in the pharmaceutical industry."

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

SOURCE Mylan Laboratories Inc.

09/15/2005

CONTACT: Public Relations, Patrick Fitzgerald, +1-724-514-1800, or

Investor Relations, Kris King, +1-724-514-1800, both of Mylan Laboratories

Web site: <http://www.mylan.com>

(MYL)